1. Covering the Cover Gastroenterology
Anson W. Lowe, Richard H. Moseley 
Gastroenterology 
Volume 143, Issue 3, Pages (September 2012)
DOI: /j.gastro
Copyright © 2012 AGA Institute Terms and Conditions

2. Figure 1 The presence of subsquamous adenocarcinoma following RFA.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

3. Figure 2
Placement of a supportive membrane containing the cultured cell sheets.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

4. Figure 3
Expression of US28 exacerbates the development of polyps induced by HB-EGF. (A) Increased incidence of serrated polyps in HBUS mice (n = 85) compared with HBGF mice (n = 34). (B) Polyp in the cecum of an HBUS mouse. (C–E) H&E-stained sections of ceca from (C and D) HBUS mice and a (E) human serrated polyp showing the presence of serrated crypts. (D and E) Arrows indicate representative serrated crypts. (F) Focus of dysplasia in a serrated polyp from an HBUS mouse (arrows). Inset shows a higher magnification of a dysplastic crypt (arrows indicate a dysplastic transition). ***P < Scale bars: (C–F) 100 μm.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

5. Figure 4
SVR by IL-28B rs genotype and HCV-RNA level at week 4 and by HCV-RNA detectability at week 8 for previously untreated patients (SPRINT-2; A, B) and previous treatment failure patients (RESPOND-2; C, D). PR48, peginterferon alfa-2b-ribavirin plus boceprevir placebo for 44 weeks; BOC RGT, response guided therapy, whereby patients with undetectable HCV-RNA at week 8 received shorter (28 weeks SPRINT-2, 36 weeks RESPOND-2) duration of peginterferon alfa-2b-ribavirin plus boceprevir; BOC/PR48, peginterferon alfa-2b-ribavirin plus boceprevir for 44 weeks.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions